GO
Loading...

Roche Holding AG

More

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • *Q1 sales 11.496 bln Swiss francs vs 11.887 bln forecast. ZURICH, April 15- Adverse currency moves weighed on first-quarter sales at Roche Holding AG, which fell 1 percent, despite a healthy uptake of its new cancer medicines.

  • Flu drug stockpiles a waste of money: Report Thursday, 10 Apr 2014 | 6:27 AM ET

    The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.

  • April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. Alkermes success comes about a week after Australia- based Prana Biotechnology said its experimental drug to treat Alzheimer's disease failed a mid-stage study.

  • April 4- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.

  • LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.

  • March 31- Prana Biotechnology Ltd lost nearly three-quarters of its value after the company said its experimental drug to treat Alzheimer's disease failed a mid-stage study, raising doubts about the drug's future.

  • March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis acquired the license to develop and market the treatment from Genentech, a unit of the Roche Holding AG, for an upfront payment of $9.5 million in November 2012.

  • *Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.

  • CHICAGO, March 10- While it is hard to knock the advice of Warren Buffett, whose annual letter to Berkshire Hathaway Inc shareholders recently lofted down from the mountain of capitalism, some of his tips can be tweaked.

  • The biotech drug lebrikizumab, which was developed by Roche Holding's Genentech unit, was tested at three doses in patients whose asthma was not sufficiently controlled even with high-dose, inhaled corticosteroids and a second asthma-controlling therapy.

  • COLUMN-Finding nooks of growth in a sluggish Europe Monday, 3 Mar 2014 | 12:27 PM ET

    CHICAGO, March 3- While the euro zone presents the unalluring face of sluggish growth, that doesn't mean it should be neglected. The reason for the negativity stems from concerns over conflict in Ukraine and reported euro zone growth at 0.3 percent in the fourth quarter.

  • DIARY-U.S. FDA advisory meetings through April 1 Friday, 21 Feb 2014 | 12:23 PM ET

    For more information on the FDA's Advisory Committee meetings, see: http://www.fda.gov/AdvisoryCommittees/Calendar/default. htm. LOCATION: College Park Holiday Inn, Ballroom, 10000 Baltimore Ave., College Park, Md..

  • Asian shares mostly higher, Nikkei rallies 3% Friday, 21 Feb 2014 | 5:51 AM ET

    An upbeat handover from Wall Street on Thursday inspired gains in most Asian shares on Friday.

  • *Market upbeat as Wall Street shrugs off weak China survey. TOKYO, Feb 21- Japan's Nikkei average jumped more than 2 percent on Friday, recouping most of the previous day's losses, as investors took heart from gains on Wall Street after a reading on U.S. manufacturing hit its highest in nearly four years.

  • Feb 11- An advisory panel to the U.S. Food and Drug Administration said on Tuesday that available evidence does not prove that the painkiller naproxen, sold under the brand names Aleve and Naprosyn, carries a lower cardiac risk than rival products.

  • Feb 11- An advisory panel to the U.S. Food and Drug Administration voted on Tuesday that there is not enough evidence to show conclusively that the painkiller naproxen carries a lower cardiac risk than other popular products.

  • Is Switzerland closed for business? Monday, 10 Feb 2014 | 4:37 AM ET
    Geneva, Switzerland

    Sunday's vote in Switzerland has raised fears that the measure is the latest in a long list of reforms that could curb the country's business-friendly environment.

  • Swiss vote to set limits on immigration from EU Monday, 10 Feb 2014 | 1:21 AM ET

    Swiss voters on Sunday narrowly backed proposals to reintroduce immigration quotas with the European Union, Swiss television reported.

  • MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

Most Popular Video

Thursday, 17 Apr 2014 | 5:00 AM ET

Today is CNBC's 25th anniversary. There have been a lot of great moments in the network's history. Here are just a few.

Thursday, 17 Apr 2014 | 3:15 AM ET

Jonny Forsyth, global drinks analyst at Mintel, says China has been a "cash cow" for drink-makers, but the slowdown is having a big impact on sales.

Thursday, 17 Apr 2014 | 1:35 AM ET

CNBC's Helia Ebrahimi discusses the Co-Operative's troubled story from drug buying allegations against the former chairman, to big financial black holes.